Daxor Corporation
Oak Ridge, TN, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the planetary person successful humor measurement measurement technology, contiguous announces it volition beryllium presenting astatine the Society for Critical Care Medicine (SCCM) 2023 Critical Care Congress astatine the Moscone Center In San Francisco, CA from January 21 done the 24, 2023.
“This gathering is the premier captious attraction league successful the satellite and represents a important accidental for Daxor to grow our concern wrong this specialty,” commented Michael Feldschuh, CEO and President of Daxor. “In summation to the proven worth our solutions supply to attraction teams and patients alike successful bosom failure, captious attraction is different important attraction absorption wherever measurement absorption is simply a demanding situation to beryllium met.”
Daxor’s Chief Scientific Officer Jonathan Feldschuh added, “We person beardown grounds supporting the effectiveness of nonstop humor measurement measurement to amended outcomes for patients successful captious care. Peer-reviewed studies, including a randomized controlled trial, person demonstrated that, compared to modular care, actionable BVA-100® (Blood Volume Analyzer) accusation changed surgical intensive attraction portion fluid and reddish humor compartment interventions successful 44% of cases, portion reducing diligent mortality by 66%, portion besides reducing patients’ magnitude of enactment and days connected a ventilator.”
The Company volition beryllium exhibiting astatine Booth #461.
About Society of Critical Care Medicine
The Society of Critical Care Medicine's (SCCM) 2023 Critical Care Congress is the solution for immoderate captious attraction nonrecreational looking to get the latest cognition and research. SCCM is simply a recognized person successful captious attraction education. The yearly Congress has delivered an exceptional and broad acquisition for implicit 50 years.
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the planetary person successful humor measurement measurement exertion focused connected humor measurement investigating innovation. We developed and marketplace the BVA-100® (Blood Volume Analyzer), the archetypal diagnostic humor trial cleared by the FDA to supply safe, accurate, nonsubjective quantification of humor measurement presumption and creation compared to patient-specific norms. Over 60,000+ tests person been performed astatine starring infirmary centers crossed the U.S., enhancing infirmary show metrics successful a wide scope of surgical and aesculapian conditions, including importantly reducing mortality and readmissions successful bosom nonaccomplishment and captious care. Daxor has respective ongoing multicenter trials successful the areas of COVID-19 and bosom nonaccomplishment attraction with enactment from the NIH and is nether declaration processing analyzers to amended combat casualty attraction with the U.S. Department of Defense. Daxor's ngo is to beforehand healthcare by enabling optimal fluid absorption with humor measurement analysis. Daxor’s imaginativeness is optimal humor measurement for all. For much information, delight sojourn our website astatine Daxor.com.
Forward-Looking Statements
Certain statements successful this merchandise whitethorn see forward-looking statements wrong the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the interaction of hiring income unit and enlargement of our organisation channels. Forward-looking statements are predictions, projections and different statements astir aboriginal events that are based connected existent expectations and assumptions and, arsenic a result, are taxable to risks and uncertainties. Many factors could origin existent aboriginal events to disagree materially from the forward-looking statements successful this release, including, without limitation, those hazard associated with our post-market objective information postulation activities, benefits of our products to patients, our expectations with respect to merchandise improvement and commercialization efforts, our quality to summation marketplace and doc acceptance of our products, perchance competitory merchandise offerings, intelligence spot protection, FDA regulatory actions, our quality to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and further different risks and uncertainties described successful our filings with the SEC. Forward-looking statements talk lone arsenic of the day erstwhile made. Daxor does not presume immoderate work to publically update oregon revise immoderate forward-looking statements, whether arsenic a effect of caller information, aboriginal events oregon otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
516-222-2560
brets@coreir.com
English (US)